Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Surf;
Thnx for feedback and reevaluation. Great help.
GL
mlkr
Surf you are da man! thnx! What is next move here?
tia
GL
mlkr
Took off the table 160 % gain.
ANR Incurs Loss as Coal Price Falls
By Zacks Equity Research | Zacks – 22 minutes ago
Email
RecommendTweet
Print
RELATED QUOTES
Symbol Price Change
ANR 9.7199 1.23
ACI 6.18 0.30
BTU 25.08 1.15
NRP 22.62 0.37
Coal producer Alpha Natural Resources (ANR) reported a loss of 19 cents per share for the fourth quarter of 2012, much narrower than the Zacks Consensus Estimate of a loss of 53 cents. The loss per share in the quarter was however wider than the year-ago loss of 9 cents.
GAAP loss during the quarter was 58 cents per share versus a loss of $3.62 per share incurred in the year-ago quarter. The difference between GAAP and operating loss in the reporting quarter was primarily due to impairments and restructuring charges.
The company’s 2012 operating loss was 94 cents per share, much narrower than the Zacks Consensus Estimate of a loss of $1.27 per share. However, the performance during 2012 was substantially lower than 2011 earnings of $1.59 per share.
Total Revenue
Alpha Natural Resources’ total revenue of $1.56 billion in the fourth quarter was marginally lower than the Zacks Consensus Estimate of $1.58 billion. The results were also lower than the year-ago figure of $2.07 billion by 24.6%.
Alpha Natural Resources’ total revenue of $6.97 billion in 2012 was slightly lower than the Zacks Consensus Estimate of $6.98 billion. The results were also lower than the 2011 figure of $7.10 billion by 1.8%.
In 2012, the company registered a 15% increase in Freight and Handling revenues, while the 2.8% dip in Coal revenues and 22.9% decline in Other Revenues resulted in overall decline.
Highlights of the Release
Coal shipment in 2012 increased 2.3% to 108.8 million tons. However this did not have a positive impact on total revenue as the average per-ton realization in 2012 was lower by $2.93 per ton as against 2011.
Total cost and expenses in 2012 were $9.77 billion versus $7.72 billion in the prior year. The increase in expenses was primarily due to higher depreciation, depletion and amortization expenses, which contracted margins.
Financial Update
Cash and cash equivalents of the company as of Dec 31, 2012 were $730.7 million versus $585.9 million as of Dec 31, 2011.
Long-term debt as of Dec 31, 2012 was $3.29 billion versus $2.92 billion as of Dec 31, 2011.
Cash from operating activities during 2012 was $518.4 million versus $686.6 million in the prior year.
Guidance
The company expects to ship 81 to 92 million tons of coal in 2013, which will include 19 to 22 million tons of Eastern metallurgical coal, 25 to 30 million tons of Eastern steam coal, and 37 to 40 million tons of Western steam coal out of the PRB.
Selling, general and administrative expenses are expected to range from $140 million to $160 million for 2013. Interest expense and depreciation, depletion and amortization expense are anticipated to be in the ranges of $230 million to $240 million and $875 million to $975 million, respectively.
Capital expenditure for 2013 is expected to remain in a range of $300 million to $350 million.
Other Company Release
Arch Coal Inc. (ACI) reported fourth-quarter 2012 pro forma loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 14 cents. Peabody Energy Corporation (BTU) reported fourth-quarter 2012 pro forma loss of $1.12 per share, below the Zacks Consensus Estimate of pro forma earnings of 26 cents per share. Natural Resource Partners L.P. (NRP) reported fourth-quarter 2012 earnings of 58 cents per unit, beating the Zacks Consensus Estimate of 43 cents.
Our View
The coal producers in the U.S. are feeling the pressure of softness in coal demand. The abundant supply of natural gas and its rock bottom low prices are not helping matters. The uncertainty prevailing in Europe is also leading to lower demand for coal.
Some signs of improvement in demand for coal from China and the recent natural calamity in Australia disrupting mining operation might act as a tailwind for the company going forward.
However, the 2013 coal shipment expectation of Alpha Natural Resources was much lower than the 2012 level, which suggests that the recovery of global demand for coal will take some time. Alpha Natural Resources has a Zacks Rank #3 (Hold).
Based in Abingdon, Virginia, Alpha Natural Resources Inc was founded in 2002. The company with its subsidiaries engages in the production and selling of steam and metallurgical coal in the United States. With a market cap of $1.87 billion the company has 13,000 full time employees.
Read the Full Research Report on ANR
Nanosphere Announces Record Revenues and Placements, and Key Leadership Changes
Press Release: Nanosphere – 23 hours ago
RELATED QUOTES
Symbol Price Change
NSPH 1.80 -0.84
NORTHBROOK, IL--(Marketwire - Feb 13, 2013) - Nanosphere, Inc. ( NASDAQ : NSPH )
Business Results and Guidance:
Customer placements in 4Q12 increased to 56, up 87% over 4Q11. Annual placements of 166, up 163% over 2011.
2012 revenues were $5.1 million, a 100% increase over 2011.
FDA 510(k) clearances granted for C. difficile and 2C19 tests during 4Q12.
Gram negative blood stream infection and enteric panels set for submission to the FDA in mid-2013.
2013 guidance set at $13 million to $15 million in revenue and 200 to 250 customer placements.
Leadership Changes and Commitment of Major Shareholder:
Michael K. McGarrity promoted to President and Chief Executive Officer.
Sheli Z. Rosenberg, Michael J. Ward and Michael K. McGarrity appointed to board, and board resignations of Mark E. Slezak, Roy N. Davis, William T. White III and William P. Moffitt were accepted.
Lurie Investments entered into a twelve-month Voluntary Lock-Up Agreement for its 14.7 million co
Progenics Pharm presents updated data from Phase 1 study of PSMA ADC; PSMA ADC was generally well tolerated in patients (PGNX) 2.85 +0.07 : Co reported positive clinical data from a completed phase 1 study of PSMA ADC, an antibody-drug conjugate (ADC) designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen (PSMA). PSMA ADC was generally well tolerated in patients at doses up to and including 2.5 mg/kg, the maximum tolerated dose. Findings were presented at the 2013 Genitourinary Cancers Symposium, a meeting co-sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO). Fifty-two patients with metastatic castration-resistant prostate cancer (mCRPC) were dosed at nine dose levels. Significant antitumor activity was observed across doses ranging from 1.8 mg/kg to 2.8 mg/kg. Dose limiting toxicities, primarily neutropenia, were seen at 2.8 mg/kg. The most commonly reported adverse events were anorexia and fatigue.
Reverse split 1 for 10. $2.50 today. Float will be 1.8 millions reduced from 18m.
stox and warrants sale:$5.25
"Medgenics closes public offering of 5.6 mln shares of common stock and Series 2013-A warrants to purchase up to an aggregate of 2.8 mln shares of common stock (MDGN) 4.91 : The shares and the warrants were sold together as a fixed combination, each consisting of one share of common stock and a warrant to purchase one-half of a share of common stock, at a price to the public of $5.25 per fixed combination. The shares of common stock and warrants were issued separately. The warrants have an initial exercise price of $6.78, are currently exercisable and will expire on February 13, 2018."
Down to $3.87 today! Endeavour Intl announced earlier that drilling has been suspended on the East Rochelle well (END) 4.94 : Co announced a drilling update on the East Rochelle well (15/27-E1y) in the U.K. Central North Sea. Following a severe storm lasting several days, the co performed a routine inspection of the conductor, well head and blow out preventer systems using a Remote Operated Vehicle. Inspection of the well revealed that the cement around the top of the 36" conductor pipe, that anchors the well to the seabed floor, had been removed creating a non- uniform hole around the conductor. The hole extended approximately 4 to 7 feet in diameter and 25 feet in depth. As a result of this finding, drilling operations have been suspended on the East Rochelle well. The work to repair the cementing around the conductor pipe has been completed.
Preparations are now being made to move the Transocean Prospect rig to the West Rochelle area to commence drilling of the second production well, allowing for the start- up of the Rochelle development. The time to drill the West Rochelle production well is estimated at ~ 120 days. Once the investigation and fatigue analysis are concluded, the co anticipates that drilling operations will re-commence at East Rochelle. Endeavour is the operator of the Rochelle development and has a 44% working interest in the field located in Blocks 15/26b, 15/26c and 15/27.
Good performance indeed:
"Provides Financial Outlook for 2013
Press Release: NeoGenomics, Inc. – 3 hours ago
Email
RecommendTweet
Print
RELATED QUOTES
Symbol Price Change
NEO 3.10 0.25
FT. MYERS, Fla., Feb. 14, 2013 /PRNewswire/ -- NeoGenomics, Inc. (NEO), a leading provider of cancer-focused genetic testing services today reported its results for the fourth quarter and full year 2012.
Fiscal Year 2012 Highlights:
50% Test Volume Growth
38% Revenue Growth
181% Increase in Adjusted EBITDA
Net Income of $65K, or $0.00 per Share
Revenue for the full year 2012 was $59.9 million, a $16.4 million or 38% increase over 2011 revenue of $43.5 million on test volume growth of 50%. Average revenue-per-test decreased by 8% as a result of the expiration of the TC Grandfather Clause on June 30th, which resulted in the loss of approximately $2.6 million of revenue in the second half of the year. Despite this major regulatory change, gross margin improved slightly to 44.8% on a full-year basis from 44.7% in 2011. Total operating expenses increased by 29% from 2011, primarily as a result of a $1.7 million increase in R&D expenditures related to new test development, as well as increased personnel, depreciation and bad debt expense associated with the revenue growth. As a percentage of revenue, operating expenses improved to 42.8% in 2012 from 45.6% in 2011. Net income for 2012 was $65,000 or $0.00 per share versus a net loss of $1.2 million or ($0.03) per share in 2011. Adjusted EBITDA for the year improved by $3.9 million or 181% to $6.0 million from $2.1 million in 2011.
Fourth Quarter 2012 Highlights:
35% Test Volume Growth
16% Revenue Growth
36% Increase in Adjusted EBITDA
Net Loss of $113K, or ($0.00) per Share
Revenue for the fourth quarter 2012 was $14.9 million, a $2.0 million or 16% increase over fourth quarter 2011 revenue on test volume growth of 35%. Gross profit increased to $6.5 million, a 10% increase from the fourth quarter 2011. Total operating expenses increased by $780,000 or 14% from last year's fourth quarter, primarily as a result of a $320,000 increase in R&D expenditures related to new test development and increased personnel and depreciation expense. Net loss for the quarter was ($113,000), or ($0.00) per share, versus net income of 152,000, or $0.00 per share in last year's fourth quarter. Adjusted EBITDA improved 36% to $1.4 million versus $1.1 million in the prior year.
Douglas M. VanOort, the Company's Chairman and CEO commented, "We are very proud of our full-year 2012 results. Our industry-leading 50% growth in test volume indicates that we are clearly winning market share. Although the TC Grandfather expiration reduced revenue by $2.6 million in the second half of the year, we were still able to increase revenue by $16 million or 38% versus 2011 with just 18 sales representatives. As importantly, productivity and process improvements allowed us to grow Adjusted EBITDA by 181% versus 2011, or almost five times the revenue growth rate, and post a modest profit for the year. Our team did a phenomenal job of delivering outstanding service, attracting new clients, reducing costs, and introducing important new tests. We believe we can continue to make progress in each of these important areas in 2013."
Mr. VanOort continued, "We are also proud of our 4th quarter results. We continued to make substantial improvements in lab productivity and operating efficiency in the quarter and came very close to returning to quarterly profitability. Lab productivity increased by 15% and Adjusted EBITDA grew by 36% from last year's fourth quarter. The improvements were also significant compared with Quarter 3, 2012 as we reduced our net loss by $800,000 with only a $700,000 increase in revenue."
Mr. VanOort concluded, "We are particularly proud of the level of innovation and new test development that we are accomplishing. In 2012, we introduced 29 new molecular tests, most of which use bi-directional Sanger sequencing, and built our molecular test menu to be one of the most comprehensive in the lab industry. We also launched 10-color flow cytometry and became the first lab in the country to offer this exciting new service on both a global and tech-only basis. In addition, we vastly improved our immunohistochemistry offering with dozens of new antibodies and brought up a new digital imaging platform. We also continued to expand our comprehensive FISH menu with several new test offerings including a promising new test to aid in the diagnosis of Barrett's Esophagus. We expect these new tests to drive substantial growth in 2013, and we expect that continued R&D investments will result in the commercialization of a number of new and innovative genetic tests."
2013 Financial Outlook
The Company also issued preliminary guidance for the full year and fiscal first quarter of 2013 today. For the full year 2013, the Company expects revenue of $68 - $73 million and net income of $0.03 - $0.05 per share. For the fiscal first quarter, the Company expects revenue of $15.3 - $16.0 million and net income of $0.00 to $0.01 per share. This guidance is based on organic growth in the current business and is based on the assumption that there will be no material reimbursement changes during the balance of 2013. The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance. "
Sano;
Well put.
Some bottom wishers resort to pump schemes with hope they could move PPS.
institutional ownership:
http://finance.yahoo.com/q/mh?s=anth&ql=1
What is your summary?
tia
mlkr
AMRN +1.2% (light volume, Amarin announces notification of patent allowance for U.S. application 13/614,129 related to Vascepa and FDA approved MARINE indication),
GTE +7.9% (announced oil discovery in Peru),
Stox and warrants sale @$.3.00: One large passive investor's stake (see Surf's post) : $2.50 today
Opexa Therapeutics, Inc. Announces Pricing of Common Stock and Warrant Offering
Date : 02/07/2013 @ 9:00AM
Source : Business Wire
Stock : Opexa Therapeutics, Inc. (MM) (OPXA)
Quote : 2.48 -0.06 (-2.36%) @ 2:13PM
Opexa Therapeutics, Inc. Announces Pricing of Common Stock and Warrant Offering
Opexa Therapeutics, Inc. (NASDAQ:OPXA) a company developing Tcelna™ (imilecleucel-T), a novel T-cell therapy for multiple sclerosis (MS), today announced it has priced an offering of shares of its common stock and warrants to purchase common stock in a private registered offering of 1,083,334 units at a price of $3.00 per unit, for gross proceeds of $3,250,000. Each unit consists of one share of common stock and a warrant to purchase one-half (0.50) of a share of common stock. The shares of common stock and warrants are immediately separable and will be issued separately such that no units will be issued. The warrants are exercisable immediately upon issuance, have a four-year term and an exercise price of $3.00 per share. The offering is expected to close on or about February 11, 2013, subject to customary closing conditions. All of the shares in the offering are to be sold by Opexa.
The net proceeds from these financing arrangements will be used for working capital and general corporate purposes, including the continued conduct of the Abili-T clinical study, Opexa's ongoing Phase 2b clinical trial of Tcelna in Secondary Progressive MS patients.
Dawson James Securities, Inc. acted as exclusive placement agent in connection with the offering.
This offering is being conducted pursuant to a shelf registration statement (File No. 333-185001) that was declared effective by the U.S. Securities and Exchange Commission on December 05, 2012. A prospectus supplement related to the public offering will be filed with the Securities and Exchange Commission (SEC). When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request at Dawson James Securities by e-mailing placements@djsiny.com.
About Multiple Sclerosis (MS)
MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.
While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
About Tcelna
Tcelna is a potential personalized therapy that is under development to be specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath™, Opexa's proprietary method for the production of a patient-specific T-cell immunotherapy, which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient. These attenuated T-cells are reintroduced into the patient via subcutaneous injection to trigger a therapeutic immune system response.
Opexa is currently conducting a Phase IIb study of Tcelna. Named Abili-T, the trial is a randomized, double-blind, placebo-controlled clinical study in patients who demonstrate evidence of disease progression without associated relapses. The trial is expected to enroll 180 patients at approximately 30 leading clinical sites in the U.S. and Canada with each patient receiving two annual courses of Tcelna treatment consisting of five subcutaneous injections per year. The trial’s primary efficacy outcome is the percentage of brain volume change (atrophy) at 24 months. Study investigators will also measure several important secondary outcomes commonly associated with MS, including disease progression as measured by the Expanded Disability Status Scale (EDSS), annualized relapse rate and changes in disability as measured by EDSS and the MS Functional Composite.
About Opexa
Opexa is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as MS. The Company’s leading therapy candidate, Tcelna™, is a personalized cellular immunotherapy that is in Phase IIb clinical development for MS. Tcelna is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Better reporting and follow up order of $30m : $3.23
Inox Wind ORDERER.
Press Release: AMSC – 3 hours ago
RELATED QUOTES
Symbol Price Change
AMSC 3.13 0.30
DEVENS, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- AMSC (AMSC), a global solutions provider serving wind and power grid industry leaders, today announced that it has received an order worth in excess of $30 million for wind turbine electrical control systems (ECS) from Inox Wind Limited, part of India's Inox Group of Companies. AMSC expects to begin shipments under this new order during the current quarter and complete shipments in 2014. This is the fifth and largest order that AMSC has received from Inox since the company began volume production of its 2 megawatt (MW) wind turbines, which were licensed from AMSC in May 2009.
"To date, we have installed nearly 250 MW of high-quality, reliable, cost-competitive wind turbines in India -- a solid step toward our objective of becoming India's premiere wind power company," said Devansh Jain, director of Inox Wind Limited. "We are already among India's top five wind energy companies with well respected customers including India's largest wind IPP's, private power distribution companies and prestigious government organizations. We are looking forward to continuing our rapid growth in the Indian market and working with AMSC to help India meet its energy demands with clean, emission-free power."
AMSC's ECS are an integrated, high-performance suite of power electronics systems that include the wind turbine power converter cabinet, internal power supply and various controls. Together, these systems serve as the "brains" of the wind turbine and enable reliable, high-performance operation by controlling power flows, regulating voltage, monitoring system performance, controlling the pitch of the wind turbine blades and the yaw of the turbines to maximize efficiency.
"Since the inception of our relationship, Inox has quickly become one of AMSC's key wind turbine manufacturing partners, and India has emerged as one of our key markets," said Daniel P. McGahn, President and CEO, AMSC. "We are proud to partner with Inox, a company that is dedicated to manufacturing excellence and committed to helping India to bridge its power gap with high-performance wind turbines."
To learn more about AMSC's product offerings for the wind industry, please visit: http://www.amsc.com/windtec/index.html.
About Inox Wind Limited
Inox Wind Limited is part of the Inox Group of Companies. Inox Group is a $2 billion+, professionally managed business group, with interests in diverse businesses including Industrial Gases, Refrigerants, Engineering Plastics, Chemicals, Carbon Credits, Cryogenic Engineering, Renewable Energy and Entertainment. The INOX Group employs close to 9,000 people at more than 150 business units across the country and has a distribution network that is spread across more than 50 countries around the globe. Each INOX Group company is characterized by three distinct characteristics - early identification of a winning business idea, building it to a size of dominant market leadership in that segment, and attaining a profit leadership position through cutting-edge efficiency in operations. The Inox Group of Companies, besides Inox Wind Limited, includes Inox Air Products Limited, Gujarat Fluorochemicals Limited, Inox India Limited, Inox Renewables Limited, Inox Leisure Limited and Fame India limited. More information is available at www.inoxwind.com.
About AMSC (AMSC)
AMSC generates the ideas
ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Last update: 2/11/2013 8:00:00 AM
SAN DIEGO, Feb. 11, 2013 /PRNewswire via COMTEX/ -- ADVENTRX Pharmaceuticals, Inc. (nyse mkt:ANX) today announced that it has initiated dosing in a thorough QT/QTc study (TQT study) of ANX-188.
Brian M. Culley, Chief Executive Officer, said: "Consistent with our guidance from October 2011 and our commitment to FDA, we have initiated this study before the end of the first quarter. We were pleased with the discussion we had with the Agency on the study protocol and our agreement on the supra-therapeutic dose."
Santosh Vetticaden, Chief Medical Officer, said: "The FDA requires an assessment of cardiac repolarization for most new drugs having systemic bioavailability. This study will assess whether or not ANX-188 has an effect on QT prolongation. The study should complete dosing in the first quarter, and we expect to announce results in the second quarter of 2013."
The objective of the TQT study is to evaluate the effect of therapeutic and supra-therapeutic doses of ANX-188 on cardiac ventricular repolarization, specifically the QT-interval, in healthy volunteers. The study is a single center, four-period, four-way cross-over, placebo- and positive-controlled, double-blind, randomized trial. Sixty subjects will be enrolled. Each subject will receive each of four treatments (placebo, active control, ANX-188 therapeutic dose, ANX-188 supra-therapeutic dose) during each of the four treatment periods.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company is recruiting subjects in EPIC, a randomized, double-blind, placebo-controlled phase 3 study of ANX-188 in patients with sickle cell disease. More information can be found on the Company's web site at .
BRIEF-EnteroMedics drops 50 pct, device fails study $1.27
NEW YORK | Fri Feb 8, 2013 7:48am EST
Feb 8 (Reuters) - EnteroMedics Inc : * Shares drop 50 percent in premarket after device fails study
EnteroMedics Inc
ETRM.O
$1.28
-1.56-54.93%
BRIEF-EnteroMedics drops 50 pct, device fails study
Down to $4 with earnings report: See Surf's post. $4
RBS settled with fine, 6 dismissals. $10s today.
RBS Pays $612.6M in Fines to US, UK Regulators
Last update: 2/6/2013 8:17:14 AM
By Max Colchester
LONDON--Royal Bank of Scotland Group PLC (RBS) said Wednesday that it paid $612.6 million in fines to U.S. and U.K. regulators over allegations that the bank sought to rig interbank lending rates, the third lender to be punished in a global probe into rate fixing.
In a statement, RBS said that it settled with the U.K. Financial Services Authority, the U.S. Commodity Futures Trading Commission and the U.S Department of Justice around allegations that traders attempted to manipulate a series of benchmark interest rates, including the London Interbank Offered Rate, or Libor.
The bank agreed to pay of GBP87.5 million to the FSA, $325 million to the CFTC and $150 million to the DoJ to resolve the investigations.
As part of the agreement with the Department of Justice, RBS entered into a Deferred Prosecution Agreement in relation to one count of wire fraud and one count for an antitrust violation.
RBS said that wrongdoing was predominantly linked to 21 employees. All these employees have either left the bank or been disciplined, the bank said.
RBS also said that investment banking chief John Hourican would leave the bank, despite having no role in the alleged rigging of rates. None of the regulators concluded that RBS, as a company, had engaged in any deliberate misconduct, the bank added. RBS said that there were no findings to suggest that senior management at the bank looked to artificially lower submissions.
The findings broadly centered on RBS's setting of the yen, Swiss franc and U.S. dollar submission, RBS said.
"The RBS Board acknowledges that there were serious shortcomings in our systems and controls and also in the integrity of a small group of our employees," RBS Chairman Philip Hampton said in a statement. "This is a sad day for RBS, but also an important one in continuing to put right the mistakes of the past."
(END) Dow Jones Newswires
February 06, 2013 08:43 ET (13:43 GMT
One downgrade: BKIR 0.136 euro. IRLBF Should be araound $0.175 at most.IRE $8.34 still manipulated.
Bank of Ireland Cut to Underperform From Neutral by Credit Suisse
Last update: 2/6/2013 1:53:50 AM
(END) Dow Jones Newswires
February 06, 2013 01:53 ET (06:53 GMT)
$1.50 ProPhase: Matrixx Initiatives withdraws acquisition offer of $1.60/share for ProPhase Labs (PRPH) 1.70 :
Listing requirements; 0.55
China Botanic Pharma announces receipt of notice of failure to satisfy continued listing requirements (CBP) 0.55 : In order to maintain its listing, the Company must submit a plan of compliance by February 14, 2013 advising of actions that Company has taken or will take to comply with Sections 134 and 1101 of the Company Guide by May 1, 2013. The Compliance Department will evaluate the Compliance Plan and make a determination as to whether or not to accept the Compliance Plan by May 1, 2013. In the event the Compliance Plan is accepted, the Company will remain listed during the plan period and will be subject to periodic review to determine whether progress is being made pursuant to the Compliance Plan. In the event that a Compliance Plan is not submitted, accepted or progress is not made under the Compliance Plan during the plan period, the Exchange staff may initiate delisting proceedings in accordance with Section 1010 and Part 12 of the Company Guide. The Company intends to submit a Compliance Plan by February 14, 2013 and continues its efforts to file the Form 10-K at the earliest possible time.
Reported:Loss reduced $1.84
Origin Agritech reported a Q1 net loss of (RMB0.98) vs a net loss of (RMB1.48) a year ago; revenue fell 15.6% to RMB22.7 (or $3.6 mln) (SEED) 1.82 : Government support
The Chinese government has recently increased its efforts to support leading crop seed companies, especially companies with national Breed-Produce-Distribute Vertically-Integrated Crop Seed Licenses (BPDVI License). As one of the first 32 companies nationwide to have been awarded the BPDVI seed license, Origin has received RMB13.6 mln (US$2.2 million) in government subsidies from various levels of the government during the first quarter. These subsidiaries are booked under "other payables and accrued expenses" on the balance sheets. With increasing government attention focused on crop seed technologies, further government supports are expected to help strengthen the Company's leading position in seed technology, production, and distribution.
Hyperion Therapeutics confirms its RAVICTI (glycerol phenylbutyrate) liquid received FDA approval for treatment of urea cycle disorders (HPTX) 16.13 +0.50 : Co announced that the FDA has approved RAVICTI for the treatment of Urea Cycle Disorders (UCD) in patients two years of age and older. The drug is expected to be commercially available by the end of April 2013.
Separately, co announced it has received notification from the U.S. Patent & Trademark Office (USPTO) of the allowance of the claims of patent application number 13/417,137 entitled, METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS, which discloses optimal measurement timing and target levels for blood ammonia in UCD patients. The issued patent would have a term that expires in March 2032. After issuance, Hyperion plans to list this patent in FDA's Approved Drug Products with Therapeutic Equivalence, or Orange Book.
Insiders activity: steady purchase to support price level $0.64 today
http://finance.yahoo.com/q/it?s=ATRM+Insider+Transactions
CAS main shareholder won: appoints 5 members to board
PRE-SPLIT PPS levels for all 3 interlinked off-spring entities : GALE (GALT) pre-split PPS is $0.40. SO CYTR $0.30; RXII $0.007!
RXII $0.0744 so typical fuvk...g CYTR $0.30 pre-split PPS ! GALE $2.54 vs its last spin off RXII 0.0744 !
Tellabs Shares Drop After Forecast Misses Estimates: WORST THAN ERALIER REPORT. $2.16
By Niamh Ring - Feb 1, 2013 9:36 AM ET
Tellabs Inc. (TLAB) fell to a 20-year low after forecasting first-quarter revenue that trailed analysts’ estimates and announcing a plan to discontinue its 9200 routing product and cut expenses.
Tellabs dropped 5.5 percent to $2.16 at 9:34 a.m. in New York, the lowest price since August 1993. The stock tumbled 44 percent last year while the S&P Midcap Information Technology Sector Index advanced 15 percent.
The company, which introduced the network-routing platform 9200 in 2011, said yesterday that it will be discontinued this year. Cutting expenses will affect about 300 positions, according to a statement from the Naperville, Illinois-based company, which according to its website employs about 2,600.
“Over the last quarter, Tellabs initiated a review of its strategy, product portfolio and cost structure,” Chief Executive Officer Dan Kelly said in the statement. The company plans to “demonstrate new software-defined networking and self- optimizing networks capabilities at Mobile World Congress in February,” he said.
The company forecast first-quarter revenue of $205 million to $220 million. That compared with an average analyst estimate of $238.9 million, according to data compiled by Bloomberg.
To contact the reporter on this story: Niamh Ring in New York at nring@bloomberg.net
To contact the editor responsible for this story: Kevin Miller at kmiller@bloomberg.n
Stox sales short period of time : First small number @ 0.95 now a large lot @ 0.75.
Secondary offering by a selling share holder @$8: $8.50 today
Adecoagro S.A. prices secondary offering of 13.9 mln common shares offered by selling shareholders at $8.00 per share (AGRO) 8.18 :
REPORTED: $2.51 Corinthian Colleges misses by $0.01, reports revs in-line; guides Q3 EPS below consensus, revs below consensus (COCO) 2.62 : Reports Q2 (Dec) earnings of $0.05 per share, $0.01 worse than the Capital IQ Consensus Estimate of $0.06; revenues fell 1.4% year/year to $409.7 mln vs the $408.57 mln consensus.
CYTR pre-split pps is $0.32 at current level of $2.16. GALT with new drug application today is $2.56. How about RXII? Anything new with their spin off?
"Galectin Therapeutics submits Investigational New Drug Application for the treatment of fatty liver disease (GALT) 2.65 : Co announces it submitted an Investigational New Drug application to the FDA on January 30, 2013. The IND application supports a proposed indication of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis, or fatty liver disease.
The IND application includes twenty seven (27) individual studies that characterize the pharmacology, pharmacokinetics, and toxicology of GR-MD-02 in a number of animal species, including the effects in various animal models of disease. Additionally, the application describes the manufacture of the drug substance and drug product to be used in human clinical trials. This information provides a description of how the drug works and why we believe it is likely to be safe in humans and provides a description of its possible mechanism of action in humans. "
BRIEFING
GL
mlkr
KaloBios Pharma NEW IPO: $8 a share
KaloBios Pharma priced upsized 8.8 mln share IPO at $8.00 per share, at low end of $8-9 revised expected range (KBIO) : Co expected to offer 8.3 mln shares.
Surf;
Did it too @ intra-day's low!
GL
mlkr
Halozyme Therapeutics seeing continued weakness following analyst downgrade yesterday afternoon (HALO) 6.08 -1.01 : The Biopharmaceutical company is trading 14% lower today (down 24% over past two trading days). This week's move relinquishes gains seen mid-month on updated FY13 guidance and loan agreement news.